Andy Hsieh
Stock Analyst at William Blair
(4.28)
# 1,388
Out of 4,662 analysts
352
Total ratings
48.7%
Success rate
9.2%
Average return
Main Sectors:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Initiated Coverage: Buy | n/a | $59.39 | - | 1 | Aug 18, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | n/a | $76.08 | - | 31 | Aug 14, 2026 | |
| KYNB Kyntra Bio | Maintained: Hold | n/a | $7.15 | - | 28 | Aug 14, 2026 | |
| PYXS Pyxis Oncology | Maintained: Hold | n/a | $3.37 | - | 11 | Aug 13, 2026 | |
| ALT Altimmune | Reiterated: Hold | n/a | $3.12 | - | 12 | Aug 12, 2026 | |
| AVIR Atea Pharmaceuticals | Reiterated: Buy | n/a | $5.59 | - | 11 | Aug 12, 2026 | |
| AARD Aardvark Therapeutics | Reiterated: Buy | n/a | $6.75 | - | 6 | Aug 12, 2026 | |
| KLRA Kailera Therapeutics | Maintained: Buy | n/a | $18.32 | - | 5 | Aug 12, 2026 | |
| CRDF Cardiff Oncology | Downgraded: Hold | n/a | $0.8979 | - | 18 | Aug 11, 2026 | |
| LNTH Lantheus Holdings | Reiterated: Hold | n/a | $100.48 | - | 18 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $54.13 | - | 11 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $54.39 | - | 59 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.99 | - | 16 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $10.75 | - | 14 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $35.98 | - | 39 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.7129 | - | 5 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.3059 | - | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $50.00 | - | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.6023 | n/a | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.13 | n/a | 15 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.722 | n/a | 22 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $147.60 | n/a | 1 | Feb 12, 2019 |
Enliven Therapeutics
Aug 18, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $59.39
Upside: -
Nektar Therapeutics
Aug 14, 2026
Maintained: Buy
Price Target: n/a
Current: $76.08
Upside: -
Kyntra Bio
Aug 14, 2026
Maintained: Hold
Price Target: n/a
Current: $7.15
Upside: -
Pyxis Oncology
Aug 13, 2026
Maintained: Hold
Price Target: n/a
Current: $3.37
Upside: -
Altimmune
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.12
Upside: -
Atea Pharmaceuticals
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.59
Upside: -
Aardvark Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.75
Upside: -
Kailera Therapeutics
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $18.32
Upside: -
Cardiff Oncology
Aug 11, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.8979
Upside: -
Lantheus Holdings
Aug 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $100.48
Upside: -
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $54.13
Upside: -
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $54.39
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.99
Upside: -
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $10.75
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $35.98
Upside: -
Jul 29, 2026
Maintained: Buy
Price Target: n/a
Current: $0.7129
Upside: -
May 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.3059
Upside: -
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $50.00
Upside: -
Aug 7, 2025
Reiterated: Buy
Price Target: n/a
Current: $0.6023
Upside: n/a
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $1.13
Upside: n/a
Dec 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $0.722
Upside: n/a
Feb 12, 2019
Maintained: Buy
Price Target: n/a
Current: $147.60
Upside: n/a